RhumbLine Advisers
MGNX icon

RhumbLine Advisers’s MacroGenics MGNX Stock Holding History

RhumbLine Advisers’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-87,215
Closed -$111K – 4213
2025
Q1 		$111K Buy
87,215
+1,998
+2% +$5.22K ﹤0.01% 3359
2024
Q4 		$277K Buy
85,217
+2,550
+3% +$9.19K ﹤0.01% 3036
2024
Q3 		$272K Sell
82,667
-5,627
-6% -$21.9K ﹤0.01% 3074
2024
Q2 		$375K Sell
88,294
-4,805
-5% -$46.8K ﹤0.01% 2859
2024
Q1 		$1.37M Buy
93,099
+2,650
+3% +$40.1K ﹤0.01% 2090
2023
Q4 		$870K Sell
90,449
-225
-0.2% -$1.55K ﹤0.01% 2341
2023
Q3 		$423K Buy
90,674
+356
+0.4% +$1.77K ﹤0.01% 2708
2023
Q2 		$483K Sell
90,318
-5,098
-5% -$31.4K ﹤0.01% 2707
2023
Q1 		$684K Buy
95,416
+1,781
+2% +$10.7K ﹤0.01% 2295
2022
Q4 		$628K Buy
93,635
+793
+0.9% +$4.35K ﹤0.01% 2357
2022
Q3 		$321K Buy
92,842
+5,055
+6% +$19.3K ﹤0.01% 2698
2022
Q2 		$259K Buy
87,787
+24,202
+38% +$127K ﹤0.01% 2833
2022
Q1 		$560K Sell
63,585
-573
-0.9% -$6.33K ﹤0.01% 2373
2021
Q4 		$1.03M Sell
64,158
-448
-0.7% -$8.43K ﹤0.01% 2193
2021
Q3 		$1.35M Buy
64,606
+2,718
+4% +$65.5K ﹤0.01% 2090
2021
Q2 		$1.66M Sell
61,888
-16,904
-21% -$495K ﹤0.01% 2026
2021
Q1 		$2.51M Sell
78,792
-5,632
-7% -$137K ﹤0.01% 1802
2020
Q4 		$1.93M Buy
84,424
+10,731
+15% +$247K ﹤0.01% 1862
2020
Q3 		$1.86M Sell
73,693
-8,878
-11% -$242K ﹤0.01% 1724
2020
Q2 		$2.31M Buy
82,571
+9,615
+13% +$167K ﹤0.01% 1647
2020
Q1 		$425K Buy
72,956
+3,570
+5% +$32.4K ﹤0.01% 2240
2019
Q4 		$755K Buy
69,386
+1,104
+2% +$10.9K ﹤0.01% 2204
2019
Q3 		$871K Buy
68,282
+4,006
+6% +$57.7K ﹤0.01% 2106
2019
Q2 		$1.09M Buy
64,276
+13,266
+26% +$228K ﹤0.01% 2029
2019
Q1 		$917K Sell
51,010
-655
-1% -$11.3K ﹤0.01% 2079
2018
Q4 		$656K Buy
51,665
+16,950
+49% +$284K ﹤0.01% 2177
2018
Q3 		$744K Sell
34,715
-2,404
-6% -$51.2K ﹤0.01% 2123
2018
Q2 		$767K Buy
37,119
+3,804
+11% +$85.7K ﹤0.01% 2130
2018
Q1 		$838K Sell
33,315
-885
-3% -$21.5K ﹤0.01% 2019
2017
Q4 		$650K Sell
34,200
-6,300
-16% -$118K ﹤0.01% 2129
2017
Q3 		$748K Buy
40,500
+395
+1% +$6.84K ﹤0.01% 2130
2017
Q2 		$702K Buy
40,105
+3,755
+10% +$71.6K ﹤0.01% 2143
2017
Q1 		$676K Buy
36,350
+222
+0.6% +$4.28K ﹤0.01% 2125
2016
Q4 		$738K Buy
36,128
+2,080
+6% +$52.4K ﹤0.01% 2014
2016
Q3 		$1.02M Buy
34,048
+935
+3% +$27.8K ﹤0.01% 1788
2016
Q2 		$894K Buy
33,113
+2,349
+8% +$53K ﹤0.01% 1857
2016
Q1 		$577K Buy
30,764
+575
+2% +$10.9K ﹤0.01% 2121
2015
Q4 		$935K Buy
30,189
+3,475
+13% +$106K ﹤0.01% 1851
2015
Q3 		$572K Buy
26,714
+2,599
+11% +$81.5K ﹤0.01% 2138
2015
Q2 		$916K Buy
24,115
+5,200
+27% +$171K ﹤0.01% 1916
2015
Q1 		$593K Buy
18,915
+3,100
+20% +$105K ﹤0.01% 2188
2014
Q4 		$555K Sell
15,815
-135
-0.8% -$3.37K ﹤0.01% 2216
2014
Q3 		$333K Sell
15,950
-100
-0.6% -$2.07K ﹤0.01% 2468
2014
Q2 		$349K Buy
+16,050
New +$337K ﹤0.01% 2498

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's MGNX Position: Q2 2025 in Review

RhumbLine Advisers sold out of MacroGenics (MGNX) in Q2 2025, closing a stake of 87,215 shares — an estimated $111K sold.

RhumbLine Advisers first reported a position in MGNX in Q2 2014 and held it in 44 quarters. The position peaked at $2.51M in Q1 2021. 112 funds tracked by Wall St. Rank hold MGNX as of Q2 2025.

  • RhumbLine Advisers reported no remaining MacroGenics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 87,215 MacroGenics shares in Q2 2025, an estimated $111K.
  • RhumbLine Advisers first reported a position in MacroGenics in Q2 2014 and held it in 44 quarters.
  • RhumbLine Advisers's MacroGenics position peaked at $2.51M in Q1 2021.
  • 112 funds tracked by Wall St. Rank held MacroGenics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.